Max Robotics — Global Service Robot Directory + US Certification

About

Wendy W.J. de Leng is a leading molecular pathologist whose work bridges cutting-edge genomics and clinical diagnostics. Her primary research focuses on the clinical implementation of whole genome sequencing (WGS) for cancer diagnostics, alongside biomarker discovery in urologic conditions. Her landmark 2021 study on the clinical validation of WGS using fresh-frozen tumor tissue and matched blood samples demonstrated that a single, all-inclusive genomic test could replace multiple targeted assays—a pivotal step toward precision oncology. This work, cited 86 times, has helped establish WGS as a viable, comprehensive tool for routine cancer care, particularly valuable when biopsy material is limited. Earlier, de Leng made significant contributions to urology, showing that elevated nerve growth factor (NGF) levels in urine could serve as a biomarker for neurogenic overactive bladder and interstitial cystitis (76 citations). Her ability to translate molecular insights into practical diagnostic tools has made her a respected figure in both cancer genomics and urologic pathology. With a career defined by rigorous validation studies and a commitment to improving patient care through molecular testing, de Leng continues to shape how clinicians integrate genomic data into everyday practice.